We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA—A PHASE II CLINICAL TRIAL.
- Authors
Jain, P.; Ok, C. y.; Fetooh, A.; Nastoupil, L.; Westin, J.; Hill, H. A.; Nair, R.; Iyer, S. P.; Steiner, R. E.; Lee, H. J.; Ahmed, S.; Kanagal‐Shamanna, R.; Jelloul, F. Z.; Castillo, L. E. Malpica; Liu, Y.; Vargas, J.; Feng, L.; Badillo, M.; Thirumurthi, S.; Xu, G.
- Abstract
I TP53 i aberration status (mutations or deletion) was available in 43/50 pts and 12 pts had aberrant I TP53 i while 31/43 did not have aberrant I TP53 i . Among 50 pts, 1 pt had recurrence of grade 2 atrial fibrillation (2%) and one pt had recurrence of grade 3 unstable angina. B Introduction: b Previously, our group reported results from ibrutinib with rituximab in older mantle cell lymphoma (MCL) patients (pts) with an atrial fibrillation rate of 22%.
- Subjects
MANTLE cell lymphoma; OLDER patients; CLINICAL trials; RITUXIMAB; NUCLEOTIDE sequencing
- Publication
Hematological Oncology, 2023, Vol 41, p150
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_99